ORYZON GENOMICS, S.A. «12345...» Page 4 out of 7 from 01/07/1988 to 23/05/2018 The price-sensitive information presented in other languages is a literal translation of the price-sensitive information stated in Spanish 24/02/2017 17:52 ORYZON GENOMICS, S.A. Board of directors remuneration annual statement La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del Ejercicio 2016 Register number: 248605 24/02/2017 17:50 ORYZON GENOMICS, S.A. Corporate governance annual report La sociedad remite el Informe Anual de Gobierno Corporativo del ejercicio 2016 Register number: 248604 24/02/2017 17:48 ORYZON GENOMICS, S.A. Interim financial information La sociedad remite información sobre los resultados del segundo semestre de 2016 Register number: 248603 24/02/2017 17:35 ORYZON GENOMICS, S.A. Information on P&L. - Others about corporate governance La Sociedad informa de los principales acuerdos adoptados en la reunión del Consejo de Administración del 23 de febrero de 2017 Register number: 248599 18/01/2017 19:07 ORYZON GENOMICS, S.A. Shareholders agreements affecting voting rights Comunication of the termination of the shareholders´ agreement and its addendum entered into by Grupo Ferrer Internacional, S.A., Najeti Capital, S.A.U., Mr. Carlos Buesa Arjol, Oryzon Genomics, S.A., Mr. José María Echarri Torres and Ms. Tamara Maes Register number: 247253 Related with 232311 of 14/12/2015 (19:39) 17/01/2017 18:27 ORYZON GENOMICS, S.A. Shareholders agreements affecting voting rights Comunication of the termination of the shareholders´ agreement and its addendum entered into by Corporación Sant Bernat, S.L. (en liquidación), ?Najeti Capital, S.A.U., Mr. Carlos Buesa Arjol, Oryzon Genomics, S.A. and Ms. Tamara Maes. Register number: 247217 Related with 232308 of 14/12/2015 (19:31) 03/01/2017 11:31 ORYZON GENOMICS, S.A. Liquidity contracts and specialists The Company submits quarterly reporting of transactions under the liquidity contract Register number: 246794 05/12/2016 21:34 ORYZON GENOMICS, S.A. R&D: new licenses, patents and registered trademarks Oryzon announces top-line results from the Phase I/IIA clinical trial with ORY-1001 Register number: 245820 16/11/2016 11:08 ORYZON GENOMICS, S.A. R&D: new licenses, patents and registered trademarks Oryzon announces that it will present Clinical Data on LSD1 Inhibitor ORY-1001 at ASH 2016 Register number: 244811 24/10/2016 16:57 ORYZON GENOMICS, S.A. Interim financial information La sociedad remite información sobre los resultados del tercer trimestre de 2016 Register number: 243932 Page 4 out of 7 «12345...»